Stay updated on CAB-ROR2-ADC: Phase 1/2 Clinical Trial
Sign up to get notified when there's something new on the CAB-ROR2-ADC: Phase 1/2 Clinical Trial page.
Latest updates to the CAB-ROR2-ADC: Phase 1/2 Clinical Trial page
- Check5 days agoChange DetectedThe update includes a glossary display option, a new 'Last Update Submitted that Met QC Criteria' label, a 'No FEAR Act Data' notice, and revision indicator (v3.4.0). Core study content, eligibility criteria, and results data remain unchanged.SummaryDifference0.1%
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe page now shows Revision: v3.3.4 instead of v3.3.3; this update does not modify study details, eligibility criteria, or other content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check41 days agoChange DetectedLocations section updated with a revised list of study sites, including additions and removals across the United States and international regions.SummaryDifference2%
- Check70 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.2.SummaryDifference0.5%
- Check77 days agoChange DetectedStandardized the Taiwan site name by replacing 'Tainan City, Taiwan' with 'Tainan, Taiwan' in the locations section.SummaryDifference0.3%
- Check91 days agoChange DetectedMinor UI updates and timestamp changes observed; core study details remain unchanged, To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
Stay in the know with updates to CAB-ROR2-ADC: Phase 1/2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CAB-ROR2-ADC: Phase 1/2 Clinical Trial page.